|Awarded On||May 18, 2016|
|Title||High affinity therapeutic mimotope antibodies to the oncogenic Epidermal Growth Factor Receptor|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Haley O Tucker|
|Cancer Sites||Leukemia, Lymphoma|
Vaccines are medicines that belong to a class of substances that work by stimulating or restoring the immune system’s ability to fight disease by producing antibodies. Treatment (or therapeutic) antibodies are intended to treat an existing cancer by strengthening the body’s natural defenses against the cancer. It is difficult to produce effective vaccines against some important cancers. These include a variety of tumors that produce on their cell surfaces very high or mutated levels of a protein called Epidermal Growth Factor Receptor (EGFR). Binding to EGFR leads to abnormally rapid cell division and migration. Thus, EGFR dysregulation can significantly contribute to the survival of tumor c...